Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Analysts estimate that CureVac will report an earnings per share (EPS) of $-0.09. Investors in CureVac are eagerly awaiting ...

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

Curevac NV announced that the FDA has cleared its IND application for a phase I clinical study of CVHNLC in patients with ...

The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.

CureVac (CVAC) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 clinical ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Novo Nordisk may miss sales expectations; federal judge fines Johnson & Johnson $1.64 billion in marketing case; CureVac mRNA ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...